SKY Apr 26 11.37 Check
BPTH Apr 26 2.83 Check
AAU Apr 19 1.35 Check
RELY Apr 13 9.93 Check
HIMX Apr 11 11.50 Check
OMEX Apr 7 8.87 Check
USCR Mar 30 63.67 Check
BRKO Mar 10 3.51 Check
KEYW Mar 3 7.00 Check
EYES Feb 23 6.93 Check
CPXX Feb 29 2.32 Check
TRXC Feb 26 3.62 Check
SLP Feb 22 10.20 Check
VHC Feb 10 7.50 Check
AMDA Feb 3 3.18 Check
ADAT Jan 28 5.0 Check
LPTH Jan 26 3.27 Check
AMSC Jan 20 6.17 Check
WNDW Jan 14 3.45 Check
NG Jan 7 4.33 Check
OLED Dec 12 53.67 Check
NCTY Dec 10 3.85 Check
PAYC Dec 2 44.02 Check
ZAGG Dec 1 10.45 Check
CALL Nov 25 10.23 Check
VLTC Nov 24 8.60 Check
TITN Nov 17 12.40 Check
BMI Nov 3 60.47 Check
HEAR Oct 26 3.45 Check
MNGA Oct 22 1.47 Check
MEET Oct 16 2.40 Check
WIFI Oct 8 8.10 Check
AVXLD Oct 6 5.80 Check
TRCH Sept 24 2.09 Check
CLIR Sept 16 6.79 Check
FENX Sept 10 9.49 Check
FTK Sept 2 20.27 Check
GTT Aug 27 22.40 Check
EFOI Aug 19 17.89 Check
VG Aug 11 6.40 Check
TRUP Aug 10 8.43 Check
TCX Aug 8 26.41 Check
LJPC Jul 13 32.87 Check
KRNT Jul 6 14.72 Check
UEC Jun 18 2.61 Check
EMAN Jun 11 2.90 Check
NWBO Jun 10 10.29 Check
DMRC Jun 3 30.00 Check
ICLD May 29 3.15 Check
PTBI May 28 9.10 Check
HOTR May 19 3.98 Check
CDTI May 15 2.25 Check
GEVO May 13 5.68 Check
QNST May 12 5.52 Check
CLNE May 5 10.10 Check
CHOP Apr 24 3.72 Check
INUV Apr 16 2.92 Check
UNXL Apr 10 7.31 Check
HRTX Apr 4 14.25 Check
MVIS Mar 23 4.02 Check
CRMD Mar 19 8.35 Check
RESN Mar 10 14.47 Check
ANTH Mar 9 6.16 Check
EYES Mar 2 17.66 Check
BLDP Feb 19 2.71 Check
ONDK Feb 11 17.51 Check
JMBA Feb 9 16.50 Check
MIFI Feb 9 5.47 Check
ZIOP Jan 16 8.23 Check
FRPT Dec 11 18.90 Check
RDCM Dec 3 10.36 Check
RCPT Nov 17 106.55 Check
URRE Nov 13 2.49 Check
PHMD Oct 29 4.16 Check
IBIO Oct 23 1.77 Check
VIMC Oct 23 9.64 Check
SZYM Oct 16 6.96 Check
AXDX Oct 14 27.38 Check
GLUU Oct 7 5.12 Check
MILL Sept 19 4.96 Check
DGLY Sept 16 20.65 Check
MNDL Aug 26 5.35 Check
FCEL Aug 20 2.76 Check
SYMX Aug 7 1.20 Check
ADES July 11 22.70 Check
TTGT June 19 8.19 Check
ANY.V May 28 9.42 Check
CYBX Apr 16 62.24 Check
OPTT Apr 4 4.19 Check
MDXG Mar 21 7.01 Check
AMRS Mar 7 4.85 Check
UNIS Feb 27 4.65 Check
PHMD Oct 17 15.49 Check
TXMD Feb 14 6.36 Check
SGMO Sept 19 11.21 Check
ZEN.V Sept 9 3.78 Check
XONE Aug 28 71.90 Check
TEAR Aug 1 14.40 Check
CNDO July 15 8.65 Check
RVLT July 2 4.03 Check
LOTE May 5 10.00 Check
LULU April 18 71.34 Check
PSSI Oct 3 23.00 Check
TNGO Aug 28 19.55 Check
MDVN May 31 $85.01 Check
JIVE May 3 $24.09 Check
SNPK April 3 $1.70 Check
QCOR Jan. 11 $41.54 Check
BRLI Nov. 1 $20.04 Check
PANL Oct. 3 $47.94 Check
GORO Aug. 23 $24.32 Check
MILL July 28 $7.04 Check
CIGX June 30 $4.51 Check
JAMN May 16 $5.17 Check
SWSH May 2 $8.77 Check
LEXG April 26 $4.02 Check
NOG March 21 $28.25 Check
VOG March 21 $5.02 Check
HNHI Feb. 17 $1.46 Check
IBIO Feb. 10 $5.17 Check
COUGF Feb. 1 $3.36 Check
LLEN Jan. 11 $10.27 Check
HHWW Dec. 23 $1.63 Check
CYDE Dec. 2 $3.29 Check
SMED Oct. 14 $5.87 Check
RMCP Sept. 21 $0.69 Check
INET Sept. 13 $10.66 Check
CLKZ Aug. 30 $0.53 Check
LQMT Aug. 19 $0.76 Check
LOCM Aug. 4 $6.12 Check
ESPH June 25 $1.49 Check
APOL June 15 $47.60 Check
BPI June 15 $19.63 Check
SILA May 27 $1.14 Check
FLPC May 27 $0.97 Check
AMEL May 27 $1.05 Check
STP May 17 $10.62 Check
BGBR April 26 $1.21 Check
NNLX April 16 $1.10 Check
CHTL April 9 $0.74 Check
AMLM March 25 $1.02 Check
LTUM March 25 $1.25 Check
TRGL March 11 $9.56 Check
TSHO Feb 24 $1.16 Check
CSKI Feb 19 $18.30 Check
GXDX Feb 15 $31.69 Check
JYHW Jan 19 $1.83 Check
AENY Jan 19 $4.51 Check
CLRH Dec 08 $1.35 Check
NXTH Dec 08 $2.28 Check
IMGG Nov 22 $1.39 Check
MEVT Nov 16 $0.35 Check
AWSL Nov 16 $3.29 Check
FRPT Oct 13 $5.84 Check
AEHI Oct. 4 $0.87 Check
URRE Nov 13 2.49 Check

The best new website for learning about penny-stock scams.

Great Panther Silver (GPL): Perfectly Priced To Cave In?

by Sonya Colberg, Senior Editor, 5/2/2016 11:03:54 AM

Great Panther Silver (NYSE: GPL) stands at the brink of a teeth-chattering stock decline.

Over the course of the past year and a half, stock in the Canadian silver mining company settled in below $1 per share, sometimes falling to 30 cents.

Then shares suddenly blew up. Did this happen because the company hit a rich vein of silver?

Not at all. Rather than Panther suddenly hitting on fortune and reversing shareholders' negative return on equity, the stock has been shored up by ambitious stock promoters. Now Great Panther appears perfectly priced to drop.

Here are the top six reasons TheStreetSweeper is shouting, "Look out below!"

*1. Why Great Panther's Stock Is Up: Jonathan Lebed Special

After seven months of trading between ~40 cents and ~$1 per share, Panther stock suddenly blew up in late April:

(Source: Nasdaq)

What happened? Well, Panther can primarily thank a well-known stock promoter.

Indeed, last Thursday, on April 28, 2016, National Inflation Association sent out a stock promotion to thousands of email recipients. The hype began like this:

(Source: National Inflation Association)

Despite the name of the sender, this email and others like it have nothing to do with the organization's purported mission of fighting inflation. NIA is not some quasi-governmental agency sworn to help people but instead is all about enriching the NIA.

Jonathan Lebed is the main man standing behind the NIA's flimsy curtain of respectability. Mr. Lebed attracted national attention in 2001 when the Securities and Exchange Commission accused the then-teenager of manipulating stock in a pump-and-dump scheme. Without admitting any wrongdoing, he settled for $285,000.

Mr. Lebed commented:

(Source: New York Times )

Mr. Lebed has been a key figure in stories by TheStreetSweeper and publications such as The New York Times, which wrote of Mr. Lebed's stock trading activities:

"This type of stock fraud is hardly victimless. When a stock price rose from $1.38 to $4.69 on the strength of his false recommendations, then fell to $1.88 after his manipulation stopped, there were winners and losers."

The recent NIA/Johnathan Lebed promotion on Panther is merely the latest in a long string of hype that has inflated the stock.

Mr. Lebed has been cheerleading Panther periodically since 2014. Back in August 2014, emailed a promotion to thousands mentioning Panther under its Toronto Stock Exchange trading symbol of GPR. The hype said in part:

There's a huge fundamental problem with promoted stocks, arguably most especially those promoted by Mr. Lebed.

Such stock promotions themselves push up the share price. So the stock price increase typically is not a reflection of any good business practices or even good luck experienced by the company.

That means the share price will virtually always drop. Because there's nothing but fluff supporting the price.

*2. Kiss Of Death: Rodman & Renshaw

Panther investors need to understand two unfortunate, crucial actions by investor Rodman & Renshaw.

First, Rodman & Renshaw - which was a key institution investigated during the Chinese stock fraud issues of 2010 to 2013 - raised its target price for Panther from $1.10 per share to $1.50 on April 14.

Panther stock rose.

Next, on April 20 - six days later - the firm inked a deal with Panther for a $10 million at-the-market (ATM) facility.

By that time, the stock had jumped 33 percent from the day of the price target upgrade to $1.48 on the day Panther and Rodman & Renshaw signed the deal.

BioPath Holdings Inc. (BPTH): Why A Bad Golf Company Won't Make A Good Gene Therapy Company

by Sonya Colberg, Senior Editor, 4/26/2016 12:35:32 PM

BioPath Holdings Inc. (Nasdaq: BPTH) has swung and sliced to the right. Now it hopes investors will run after the ball. 

The company spent six years fruitlessly trying to make a buck selling ugly pants, clashing shirts and other golf paraphernalia. It eventually made the unlikely transformation into ...  gene therapy.

But BioPath is still missing the ball and almost certainly will continue to do so as this company attempts to produce a drug delivery platform.

Indeed, the new company presents these massive risks for investment portfolios:

* Reverse Merger; Inexperienced Management: The CEO/CFO/Treasurer/Chairman/President reverse merged a golf company to create a biotech. He is among the company's four leaders with virtually no experience in biotech. 

* Unfortunate Supporter: Recent support from Rodman & Renshaw is good reason for investors to avoid BioPath.

* Uncertain Revenue Generation: Any possible product sales are distant dreams. The top drug candidate is only in Phase II study. The second candidate is approaching Phase II. So the prospects must get through one to two more phases of study before even going after FDA approval to market the drug. 

* Fierce Competition: No one knows whether the drug candidates will succeed and some experts are skeptical. Meanwhile, many established companies are developing strong therapies for the same patients.

* Low Institutional Interest: Five institutions have sold out, including a particularly noteworthy investor.

* Stock Dilution Looms: BioPath's cash has fallen to an estimated $7.65 million. At a $1.25 million quarterly burn rate, it will take a significant cash transfusion to proceed with trials and business operations. A big ATM brimming with share dilution potential is poised.

Investors may find other viewpoints here. Meanwhile, here are details on the top six reasons TheStreetSweeper is convinced BioPath's drug game will be no better than its golf game.

*1. Odd Beginning

So it all began in 2000 when Ogden Golf Corp. opened and began selling golf items in Ogden, Utah.

After six straight years of losses and nothing to show for it but over-tapped friends and family, the board apparently realized the golf course would not drive the company straight to wealth and happiness. So managers registered with the Securities and Exchange Commission, began selling shares for 50 cents apiece and looked around for business ideas.

They found that idea in the most unlikely of places ...

*2. Reverse Merger; Inexperienced Management.

Two years after Ogden Golf closed, the CEO/CFO/Treasurer/Chairman/President decided to reverse merge his golf company to create BioPath Holdings in 2008.

But, while Peter Nielsen may know golfing, he lacks biotech or healthcare leadership experience. Yet here he  is - the CEO, CFO, treasurer, chairman and president of a Bellaire, Texas biotech - albeit a biotech that has failed to advance a product as far as Phase III in eight years.

Peter H. Nielsen. Mr. Nielsen is a co-founder of Bio-Path, serving as its Chief Executive Officer, President and Chief Financial Officer/Treasurer and Chairman of the Board since 2008. Mr. Nielsen has developed a close working relationship over the last six years with key individuals at The University of Texas MD Anderson Cancer Center and its suppliers. Mr. Nielsen has a broad management background in senior management, leading turnarounds of several large companies.  He also has experience in finance, product development, cost and investment analysis, manufacturing and planning.  He has also worked with several other biotech companies developing and executing on strategies for growth and previously served as a director of Synthecon, Inc., a manufacturer of 3D bioreactors.  Prior to joining Bio-Path, Mr. Nielsen served as Chief Financial Officer of Omni Energy Services Corp., a NASDAQ traded energy services company.  Mr. Nielsen was a Lieutenant in the U.S. Naval Nuclear Power program where he was Director of the Physics Department and was employed at Ford Motor Company in product development.  He holds engineering and M.B.A. finance degrees from the University of California-Berkeley.

But Mr. Nielsen's biotech experience is so light that the second line of his biography highlights his friendship with folks at The University of Texas MD Anderson Cancer Center.

While the bio states he led "turnarounds of several large companies," it mentions Synthecon, a company that seems to be a Houston Technology Center incubator product with little public presence since 2010. And it mentions an oil services company, Omni Energy Services Corp., where he became CFO in September 1999.

But the oilfield service company priced at  $11 per share in its initial public offering in 1997 soon fell into financial disarray.

Mr. Nielsen's presence there could hardly be related to any "turnaround." According to this release on a lawsuit, his predecessor claims to have been hired as part of a turn-around team because "its stock price was depressed and the company had narrowly avoided delisting."

Indeed, Omni reported gross profit worsened from $-2.7 million when he arrived to $-3.6 million, when Mr. Nielsen apparently left as he signed his last amended annual report in April 2000.

BioPath co-founder Douglas P. Morris also lacks prior biotech experience. The company director left his BioPath executive position in 2014.

Douglas P. Morris. Mr. Morris is a co-founder of Bio-Path and has served as a director of Bio-Path since 2007 and served as an officer from 2007 to June 2014. Mr. Morris currently serves as a co-founder, Managing Member, and Secretary of nCAP Holdings, LLC (nCAP), a privately held technology based company. Between 1993 and 2010, Mr. Morris was an officer and director of Celtic Investment, Inc., a financial services company. Since 1990, Mr. Morris owns and operates Hyacinth Resources, LLC (“Hyacinth”), a business-consulting firm and is also a Managing Member of Sycamore Ventures, LLC, a privately held consulting firm. Mr. Morris has a B.A. from Brigham Young University, and attended the University of Southern California Masters program in public administration.

Chief operating officer Ulrich W. Mueller (page 51) and director Dr. Amy P. Sing (page 52) both have some biotech experience. But out of six BioPath leaders, four have no significant biotech experience.

And, considering how little the 11-person company has advanced in nearly a decade, executives are generously rewarded. The two top executives haul in around $1 million yearly.

(Source: Company SEC filing)

Now, let's look at an investor that was, in our opinion, unfortunately attracted to BioPath.

*3. Unfortunate Support: Rodman & Renshaw

One reason for investors to be cautious is the April 18, 2016 $5 buy rating from Rodman & Renshaw. The note apparently helped push up the stock but a price increase is temporary ... and could suddenly reverse course. 

JAMN Finally Spills the Beans -- And It's an Ugly Mess

by Janice Shell, 6/2/2011 10:32:51 AM

* Editor's Note: Readers can access links to additional backup documents for this story by clicking here for TheStreetSweeper's original investigative report on this company.

Late Tuesday afternoon, after missing earlier deadlines, Jammin Java (OTC: JAMN.OB) filed a long-awaited annual report packed with enough eye-opening news to keep investors up all night. That mandatory filing, unaccompanied with a cheerful press release heralding its arrival, served as a painful wake-up call to shareholders already burned by a rapid plunge in the company’s stock price.

To be sure, the 10-K offered investors little reason to sing. For starters, the filing reveals, this once-hot “coffee company” sells no coffee of its own at all. JAMN relies on a supplier based in frigid Canada – far away from the tropical Jamaican home of its co-founder Rohan Marley – to provide the company with an actual product to sell to its customers instead.

Back in April of 2010, JAMN inked a “supply and toll agreement” with Canterbury Coffee of British Columbia that gave it access to some brew. According to that agreement, JAMN relies on Canterbury to fulfill every role – save a minor one – normally satisfied by a firm that classifies itself as a coffee company. Canterbury purchases the coffee beans. It roasts them. And it then packages them in bags supplied by JAMN – the company’s only real product – for sale to the public.

JAMN signed this deal more than a year ago, right before Shane Whittle – a notorious Vancouver stock promoter – officially resigned as CEO of the company. But the company never mentioned that agreement, seemingly material enough to warrant at least a quiet 8-K report, in a single regulatory filing until now.   

Jammin Java (JAMN): Hot Stock ... Bitter Aftertaste?

by Janice Shell, 6/2/2011 10:30:25 AM

It’s time to wake up and smell the coffee! That’s exactly what Jammin Java (OTC: JAMN.OB), a heavily promotedcoffee company, and – for very different reasons – TheStreetSweeper would like investors to do.

Since the beginning of the year, JAMN has miraculously risen from the ashes of the “Grey Market” graveyard to become one of the liveliest – and richest – stocks in the entire microcap arena. JAMN has seen its stock shoot straight toward heaven, soaring from 55 cents to peak above $6 a share on massive daily volume, with its market value nowtopping $355 million despite the company’s limited resources and operating history. (As covered in more detail below, two of the Internet tout sheets pushing JAMN the hardest effectively vanished -- disabled by their Internet servers -- on the day the stock’s trading volume exploded past 20 million shares.) 

JAMN stands out for its powerful connections, the first loudly celebrated by the company and the second – involving a notorious stock promoter – carefully hidden from view.


CCME: Few Signs of Life at 'Healthy' Chinese Firm

by Roddy Boyd, 3/23/2011 9:30:34 AM

* Editor's Note: This story has been republished with permission from The Financial Investigator. To access the original article, complete with links to back-up documents, click here.

In the maze of thronged and narrow streets that makes up Fujian province’s capital city of Fuzhou, a deft driver, if he’s willing–as all Chinese drivers apparently are–to nearly kill or injure vast numbers of his countrymen can take you to the foot of Dongjie street. There was little reason to be there save for its having the headquarters of a company called China MediaExpress Holdings (Nasdaq: CCME), an enterprise that seems to be able to weather allegations about its business that would have forced the share price collapse of a company five times its size. The attention of bulls and bears is not misplaced: In a mere four years as a public company, it has apparently come to dominate the ad placement market for leading multinational consumer products companies on a network of what it claims is more than 27,000 buses on Chinese airport and intercity routes.

Also, and this cannot be understated, hanging out on a sidewalk in Fujian–the sidewalks double as parking spots when the streets, which appeared to have been designed in the Han Dynasty, fill up–was not a viable option. There was also the matter of the world-class headache the Financial Investigator was developing from Fuzhou’s diabolical smell, an epic conflation of poor sewage treatment, air pollution and the smell of cabbage that made getting the hell off Dongjie street a matter of vital importance.

The Financial Investigator and his traveling companion for the trip, an American investor with extensive experience in China, decided to head upstairs despite our interview with the CFO having been cancelled at the last minute (with no explanation given.) We thought a quick tour of the offices and meeting a few other executives might open our eyes to a few things.

It did.

Though the language barrier was a little steep with the young receptionist–when we asked for writing paper, she provided Kleenex–we were in short order shown to their conference room and told to wait. It did not escape notice that pride of place in the conference room belonged to a framed certificate of participation from the Fall 2010 Rodman & Renshaw conference, the World Cup for reverse merger companies and the pumpers and touts who peddle them.

Eventually chief operating officer James Yu came down and after spending 30 minutes trying to understand who we were, concluded that giving us a tour wouldn’t hurt. Soon enough, his colleague, Vinne Ye–the chairman’s assistant–came out and took us around.

It was most eye-opening.


Signup For Alerts
When new stories are published

Barron's reports that TheStreetSweeper unravels an odd case of mistaken identity surrounding Skyline (SKY):

Read the Article
Read the SKY Story

The Street Sweeper Is Not A Fan of Glu Mobile Inc.'s Kim Kardashian Game (GLUU):

Read the Article
Read the GLUU Story

Glu Mobile Falls as Kardashian Game Drops in Rankings (GLUU):

Read the Article
Read the GLUU Story

CNBC on TheStreetSweeper's coverage of Gold Resource Corporation: (GORO):
"Herb Greenberg comments on Gold Resource Corporation"

Watch the Video
Read the GORO Story

CNBC on TheStreetSweeper's coverage of Miller Energy Resources: (MILL):
"Melissa Davis at TheStreetSweeper … wrote a piece on this thing that obviously scared investors a little bit … It was an excellent reporting job (and) has moved the stock dramatically."

Watch the Video
Read the MILL Story

Herb Greenberg's View (NOG):
"There are questions about related parties … Sometimes companies just don't pass that 'sniff test.'"

Watch the Video
Read the NOG Story

Cramer's View (SWSH): "I wouldn't touch Swisher with a 10-foot PLUNGER!"
Watch the Video
Read the SWSH Story

Cramer's View (NOG): "I clearly have been jarred by the accounting issues and feel like, right now, the momentum has left this stock."
Watch the Video
Read the NOG Story

New Article Alert! Sign up to get notified of new articles.  Click Here. Subscribe
| More

Investors must be properly armed in order to protect themselves against the dangers of Wall Street. To help out, The Street Sweeper has mined the Internet for the most powerful weapons available to investors researching publicly traded companies. In our “Loaded Weapons” section, you’ll find direct links to corporate documents filed with the SEC, conference call transcripts published by Seeking Alpha, insider stock sales tracked by and popular investment tools offered by Yahoo! Finance. You can also identify the promoters behind current penny stock campaigns – and the compensation they are receiving – by connecting to You can link to other websites that are conducting topnotch stock investigations as well. Click here now.

When investors begin their homework on small-cap companies - particularly on penny stocks - they should probably start with an important history lesson. Specifically, they should conduct background checks on their stockbrokers and the companies those brokers are touting.
The Street Sweeper has designed a cheat sheet of sorts to help out with this research. Our “Rap Sheet” section links to a free tool (sponsored by FINRA) that allows ordinary investors to review the backgrounds of individual stockbrokers and their brokerage firms. The section also links to whistleblower cases and class-action lawsuits targeting publicly traded companies. It provides access to recent news of SEC enforcement actions and FBI white-collar crime investigations as well.
click here now.